JP2005530735A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530735A5
JP2005530735A5 JP2003585723A JP2003585723A JP2005530735A5 JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5 JP 2003585723 A JP2003585723 A JP 2003585723A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
medicament
warm
creating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530735A (ja
Filing date
Publication date
Priority claimed from GB0208680A external-priority patent/GB0208680D0/en
Priority claimed from GB0218388A external-priority patent/GB0218388D0/en
Application filed filed Critical
Priority claimed from PCT/GB2003/001617 external-priority patent/WO2003088971A1/en
Publication of JP2005530735A publication Critical patent/JP2005530735A/ja
Publication of JP2005530735A5 publication Critical patent/JP2005530735A5/ja
Pending legal-status Critical Current

Links

JP2003585723A 2002-04-16 2003-04-14 癌の処置のための併用療法 Pending JP2005530735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208680A GB0208680D0 (en) 2002-04-16 2002-04-16 Combination therapy
GB0218388A GB0218388D0 (en) 2002-08-08 2002-08-08 Combination therapy
PCT/GB2003/001617 WO2003088971A1 (en) 2002-04-16 2003-04-14 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2005530735A JP2005530735A (ja) 2005-10-13
JP2005530735A5 true JP2005530735A5 (enExample) 2006-05-11

Family

ID=29252451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585723A Pending JP2005530735A (ja) 2002-04-16 2003-04-14 癌の処置のための併用療法

Country Status (16)

Country Link
US (1) US20050215530A1 (enExample)
EP (1) EP1496909B1 (enExample)
JP (1) JP2005530735A (enExample)
KR (1) KR20040103964A (enExample)
CN (1) CN100352441C (enExample)
AT (1) ATE353650T1 (enExample)
AU (1) AU2003216558B2 (enExample)
BR (1) BR0309226A (enExample)
CA (1) CA2482591A1 (enExample)
DE (1) DE60311788T2 (enExample)
ES (1) ES2280735T3 (enExample)
IL (1) IL164564A0 (enExample)
MX (1) MXPA04010166A (enExample)
NO (1) NO20044498L (enExample)
NZ (1) NZ535739A (enExample)
WO (1) WO2003088971A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004112801A2 (en) * 2003-06-18 2004-12-29 Angiogene Pharmaceuticals Limited Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
AR046337A1 (es) * 2003-10-15 2005-12-07 Osi Pharm Inc Imidazopirazina inhibidoras de las tirosinquinasas
CN1960993A (zh) * 2004-04-02 2007-05-09 Osi制药公司 6,6-双环取代的杂双环蛋白激酶抑制剂
CA2569132A1 (en) * 2004-06-03 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Similar Documents

Publication Publication Date Title
JP2006504723A5 (enExample)
JP2005511597A5 (enExample)
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
JP2005530735A5 (enExample)
JP2006500346A5 (enExample)
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL165532A (en) History of Aryl Carbonyl, Pharmaceutical Preparations Containing Them and Their Use in the Preparation of Medicines for the Treatment of Metabolic Disorders
IL178822A (en) Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
IL164373A (en) Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
EP1635762A4 (en) LOW-DOSED PHARMACEUTICAL POWDER FOR INHALATION
CL2003002287A1 (es) COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2012524089A5 (enExample)
WO2006050155A3 (en) Cancer therapeutic compositions
JP2008514577A5 (enExample)
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
ATE146361T1 (de) Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
IL179075A (en) Use of random copolymer preparations in the preparation of drugs for the treatment of diseases, the reduction of undesirable immune reactions and the treatment of multiple sclerosis and pharmaceutical preparations containing random copolymer preparations
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
SI1803456T1 (sl) Farmacevtski sestavki, ki obsegajo L-733060, za uporabo pri zdravljenju rakavih tumorjev